Kp Tissue Stock Performance

KPTSF Stock  USD 7.49  0.07  0.93%   
KP Tissue has a performance score of 15 on a scale of 0 to 100. The company owns a Beta (Systematic Risk) of -0.0528, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning KP Tissue are expected to decrease at a much lower rate. During the bear market, KP Tissue is likely to outperform the market. KP Tissue today owns a risk of 0.85%. Please verify KP Tissue maximum drawdown, and the relationship between the information ratio and expected short fall , to decide if KP Tissue will be following its current price history.

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in KP Tissue are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, KP Tissue may actually be approaching a critical reversion point that can send shares even higher in January 2026. ...more
Price Earnings Ratio85.1111
Total Cashflows From Investing Activities5.6 M
  

KP Tissue Relative Risk vs. Return Landscape

If you would invest  675.00  in KP Tissue on September 27, 2025 and sell it today you would earn a total of  74.00  from holding KP Tissue or generate 10.96% return on investment over 90 days. KP Tissue is currently producing 0.1688% returns and takes up 0.8497% volatility of returns over 90 trading days. Put another way, 7% of traded pink sheets are less volatile than KPTSF, and 97% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon KP Tissue is expected to generate 1.19 times more return on investment than the market. However, the company is 1.19 times more volatile than its market benchmark. It trades about 0.2 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.12 per unit of risk.

KP Tissue Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for KP Tissue's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as KP Tissue, and traders can use it to determine the average amount a KP Tissue's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.1986

Best PortfolioBest Equity
Good Returns
Average Returns
Small ReturnsKPTSF
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative Returns
Based on monthly moving average KP Tissue is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of KP Tissue by adding it to a well-diversified portfolio.

KP Tissue Fundamentals Growth

KPTSF Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of KP Tissue, and KP Tissue fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on KPTSF Pink Sheet performance.

About KP Tissue Performance

By analyzing KP Tissue's fundamental ratios, stakeholders can gain valuable insights into KP Tissue's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if KP Tissue has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if KP Tissue has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
KP Tissue Inc., through its interest in Kruger Products L.P., produces, distributes, markets, and sells a range of disposable tissue products in Canada and the United States. KP Tissue Inc. was incorporated in 2012 and is headquartered in Mississauga, Canada. Kp Tissue operates under Household Personal Products classification in the United States and is traded on OTC Exchange.

Things to note about KP Tissue performance evaluation

Checking the ongoing alerts about KP Tissue for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for KP Tissue help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
KP Tissue has high likelihood to experience some financial distress in the next 2 years
Evaluating KP Tissue's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate KP Tissue's pink sheet performance include:
  • Analyzing KP Tissue's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether KP Tissue's stock is overvalued or undervalued compared to its peers.
  • Examining KP Tissue's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating KP Tissue's management team can have a significant impact on its success or failure. Reviewing the track record and experience of KP Tissue's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of KP Tissue's pink sheet. These opinions can provide insight into KP Tissue's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating KP Tissue's pink sheet performance is not an exact science, and many factors can impact KP Tissue's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for KPTSF Pink Sheet analysis

When running KP Tissue's price analysis, check to measure KP Tissue's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy KP Tissue is operating at the current time. Most of KP Tissue's value examination focuses on studying past and present price action to predict the probability of KP Tissue's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move KP Tissue's price. Additionally, you may evaluate how the addition of KP Tissue to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Transaction History
View history of all your transactions and understand their impact on performance
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years